Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VULCANize2 for locally advanced vulvar carcinoma
NL-OMON60784Phase 3Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Jan 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of carboplatin, cisplatin and paclitaxel in vulvar squamous cell carcinoma (VSCC) (2 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Loco-regional control at 2 years. Started Jan 2024; status: recruiting.
02
Drugs
carboplatincisplatinpaclitaxel
03
Conditions
vulvar squamous cell carcinoma (VSCC)
Beyond the preview
Go deeper on NL-OMON60784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60784.